Rexahn Announces Multiple Presentations at the 2019 American Association for Cancer Research Annual Meeting
March 27 2019 - 7:00AM
Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage
biopharmaceutical company developing innovative therapies to
improve patient outcomes in cancers that are difficult to treat,
today announced that it will present four scientific posters at the
2019 American Association for Cancer Research (AACR) Annual
Meeting, which will be held from March 29 – April 3, 2019 in
Atlanta, Georgia.
Details of the poster presentations are as follows:
Title: Phenotyping pancreatic cancer CTCs
as biomarkers for RX-3117 clinical trialSession Date and
Time: Sunday, March 31, 2019 1:00 PM - 5:00
PMSession Title: Circulating and Cell-free
Biomarkers for Diagnosis and Monitoring of Cancer
1Location: Georgia World Conference Center,
Exhibit Hall B, Poster Section 17Abstract Number:
428 Abstract Link:
https://www.abstractsonline.com/pp8/#!/6812/presentation/7993
Title: RX-5902 exhibits direct and
immunomodulatory anti-tumor activities in melanoma PDX
modelsSession Date and Time: Tuesday, April
2, 2019 1:00 PM - 5:00 PMSession Title: Novel
Immunomodulatory Agents 2Location: Georgia
World Conference Center, Exhibit Hall B, Poster Section
25Abstract Number: 4127 Abstract
Link:
https://www.abstractsonline.com/pp8/#!/6812/presentation/3309
Title: The anticancer effects of RX-5902
result from inhibition of phosphorylated p68-mediated β-catenin
nuclear translocationSession Date and
Time: Monday, April 1, 2019 8:00 AM - 12:00
PMSession Title: Novel Targets and
PathwaysLocation: Georgia World Conference
Center, Exhibit Hall B, Poster Section 14Abstract
Number: 1298Abstract Link:
https://www.abstractsonline.com/pp8/#!/6812/presentation/5514 Title:
Unusual mechanism of resistance to the novel cytidine analog
fluorocyclopentenylcytosine (RX-3117)Session Date and
Time: Monday, April 1, 2019 8:00 AM - 12:00
PMSession Title: Drug Resistance
2Location: Georgia World Conference Center,
Exhibit Hall BAbstract Number:
1267Abstract Link:
https://www.abstractsonline.com/pp8/#!/6812/presentation/1631
Copies of the abstracts are available and can be viewed online
through the AACR website at www.aacr.org. Once
presented, copies of the posters will be available on the company’s
website
at https://rexahn.com/cms/media-center/publication/posters/.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals Inc. (NYSE American: RNN) is a clinical
stage biopharmaceutical company developing innovative therapies to
improve patient outcomes in cancers that are difficult to treat.
The Company’s mission is to improve the lives of cancer patients by
developing next-generation cancer therapies that are designed to
maximize efficacy while minimizing the toxicity and side effects
traditionally associated with cancer treatment. Rexahn’s product
candidates work by targeting and neutralizing specific proteins
believed to be involved in the complex biological cascade that
leads to cancer cell growth. Preclinical studies show that several
of Rexahn’s product candidates may be effective against multiple
types of cancer, including drug resistant cancers, and
difficult-to-treat cancers and others may augment the effectiveness
of current FDA-approved cancer treatments. The Company has two
oncology product candidates, RX-3117 and RX-5902, in Phase 2
clinical development and additional compounds in preclinical
development, including RX-0301. For more information about the
Company and its oncology programs, please visit www.rexahn.com.
Safe Harbor
To the extent any statements made in this press release deal
with information that is not historical, these are forward-looking
statements under the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about Rexahn’s plans, objectives, expectations and intentions with
respect to cash flow requirements, future operations and products,
enrollments in clinical trials, the path of clinical trials and
development activities, expected results of the Company’s planned
cost reductions, and other statements identified by words such as
“will,” “potential,” “could,” “can,” “believe,” “intends,”
“continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,”
and other words of similar meaning or the use of future dates.
Forward-looking statements by their nature address matters that
are, to different degrees, uncertain. Uncertainties and risks may
cause Rexahn’s actual results to be materially different than those
expressed in or implied by Rexahn’s forward-looking statements. For
Rexahn, particular uncertainties and risks include, among others,
understandings and beliefs regarding the role of certain biological
mechanisms and processes in cancer; drug candidates being in early
stages of development, including clinical development; the ability
to initially develop drug candidates for orphan indications to
reduce the time-to-market and take advantage of certain incentives
provided by the U.S. Food and Drug Administration; the ability to
transition from our initial focus on developing drug candidates for
orphan indications to candidates for more highly prevalent
indications; the availability and access to capital; and the
expected timing of results from our clinical trials. More detailed
information on these and additional factors that could affect
Rexahn’s actual results are described in Rexahn’s filings with the
Securities and Exchange Commission, including its most recent
annual report on Form 10-K. All forward-looking statements in this
news release speak only as of the date of this news release. Rexahn
undertakes no obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
Investor Contact:ir@rexahn.com
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Historical Stock Chart
From Apr 2023 to Apr 2024